EMA confirms clots as ‘very rare’ AstraZeneca side effect

EU health regulators say a plausible explanation for the ‘very rare’ side effects of blood clot of the AstraZeneca jab is an immune response to the vaccine. – EPA pic, April 7, 2021.

EU’S drug regulator said today that blood clots should be listed as a “very rare” side effect of the AstraZeneca coronavirus vaccine but that the jab’s benefits continue to outweigh the risks.

No specific risk factors, including age, have been identified for thrombosis with the AstraZeneca shot, which could stem from an immune response, the European Medicines Agency (EMA) said.

Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!

Subscribe Now!

Sign up or sign in here to comment.